• Skip to main content

RapCov™

Rapid COVID-19 Test

HOME

RapCov Documents

Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for emergency use of RapCov™ Rapid COVID-19 Test (EUA # 202686, approval issued on 1/11/2021).The RapCov™ Rapid COVID-19 Test is authorized to be accompanied with labeling entitled “RapCov™ Rapid COVID-19 Test” Instructions for Use, the quick reference guide “Quick Reference Instructions for RapCov™ Rapid COVID-19 Test,” and the following product-specific information pertaining to the emergency use, which is required to be made available to healthcare providers and recipients.


Expiration Date Extension of EUA202686

EUA202686 Advaite Letter of Authorization 01-11-2021

Advaite Letter Granting EUA Revision

RapCov™ Rapid COVID-19 Test – Instructions for Use

Fact Sheet for Health Care Providers

Fact Sheet for Patients

Quick Reference Instructions

NCI/NIH Evaluation Report on RapCov Rapid COVID-19 Test

Copyright © 2025 · Advaite, Inc.

  • COVID-19 Virus Disease
  • RapCov™ Test Principle
  • Performing Test & Interpretation
  • RapCov™ FDA Status
  • RapCov™ Clinical Studies
  • RapCov™ Documents
  • RapCov™ Press & Media
  • Contact Information